ASML’s EUV Monopoly Powers the Global AI Chip Boom 
UK Politicians Call for Full Competition Review of Netflix’s Warner Bros Discovery Deal 
Sam Altman Criticizes ICE Enforcement as Corporate Leaders Call for De-Escalation 
Ford and GM Near Financing Deal to Support First Brands Group During Bankruptcy 
Alibaba-Backed Moonshot AI Unveils Kimi K2.5 to Challenge China’s AI Rivals 
C3.ai in Merger Talks With Automation Anywhere as AI Software Industry Sees Consolidation 
Puma’s Historic Rivalry With Adidas Enters a New Era as Anta Deal Signals Turnaround Push 
LVMH Investors Watch Earnings Closely as Luxury Recovery Faces New Challenges 
Micron to Expand Memory Chip Manufacturing Capacity in Singapore Amid Global Shortage 
The Maire - EuroChem Case: Three Lessons for Global Business 
Volkswagen CEO Oliver Blume Faces Crucial Year as Investors Demand Turnaround Results 
Microsoft Wins Approval to Build 15 New Data Centers in Wisconsin 
ASML’s EUV Lithography Machines Power Europe’s Most Valuable Tech Company 
Boeing Posts Fourth-Quarter Profit on Jeppesen Sale Despite Ongoing Unit Losses 
Elon Musk Reportedly Eyes June 2026 SpaceX IPO Timed With Planetary Alignment and Birthday 
Tesla Loses Ground in Europe as BYD Accelerates EV Market Share in 2025 
Meta Faces Lawsuit Over Alleged Approval of AI Chatbots Allowing Sexual Interactions With Minors 
 - EconoTimes)
SOUTH SAN FRANCISCO, Calif., May 18, 2017 -- Portola Pharmaceuticals Inc.® (Nasdaq:PTLA) today announced that preclinical and clinical data on cerdulatinib in relapsed/refractory b-cell malignancies will be presented at the European Hematology Association (EHA), which is taking place from June 22-25 in Madrid, Spain.
Cerdulatinib is an investigational oral, dual SYK/JAK kinase inhibitor in development to treat patients with resistant or relapsed hematologic cancers. Cerdulatinib inhibits two key signaling pathways that promote cancer cell growth in certain hematologic malignancies.
Details regarding the presentations follow.
Oral Presentation Details:
- Presentation Title: The Dual SYK/JAK Inhibitor Cerdulatinib Demonstrates Complete Inhibition of SYK and JAK and Rapid Tumor Responses in a Phase 2 Study in Patients with Relapsed/Refractory B Cell Malignancies
- Presenter: Paul Hamlin, M.D., Memorial Sloan-Kettering Cancer Center
- Abstract Number: EHA22
- Presentation Date and Time: June 25, 2017 from 9:00-9:15 a.m. UTC
- Location: Hall A
Poster Presentation Details:
- Presentation Title: IL-4 Increases Expression of Positive Regulators of BCR Signaling in CLL Which Can Be Overcome by Cerdulatinib
- Presenter: Andrew Steele, Ph.D., Associate Professor, Medicine, University of Southampton
- Abstract Number: P587
- Presentation Date and Time: June 24, 2017 from 5:30 – 6:00 p.m. UTC
- Location: Poster Hall (Hall 7)
About Portola Pharmaceuticals, Inc.
Portola Pharmaceuticals is a biopharmaceutical company developing product candidates that could significantly advance the fields of thrombosis and other hematologic diseases. The Company is advancing three programs, including betrixaban, an oral, once-daily Factor Xa inhibitor; AndexXa™ (andexanet alfa), a recombinant protein designed to reverse the anticoagulant effect in patients treated with an oral or injectable Factor Xa inhibitor; and cerdulatinib, a SYK/JAK inhibitor in development to treat hematologic cancers. Portola's partnered program is focused on developing selective SYK inhibitors for inflammatory conditions. For more information, visit http://www.portola.com and follow the Company on Twitter @Portola_Pharma.
Investors: Ana Kapor Portola Pharmaceuticals [email protected] Media: Julie Normart Pure Communications [email protected] 415.946.1087
